Why Matinas BioPharma Stock Crashed Today
Shares of Matinas BioPharma Holdings (NYSEMKT: MTNB) were crashing 32.7% lower as of 3:01 p.m. EST on Monday. The steep decline came after the company announced disappointing results from a phase 2 clinical study of Lypdiso in reducing triglycerides.
Matinas had good news and bad news. The good news was that Lypdiso beat Amarin's (NASDAQ: AMRN) Vascepa in increasing eicosapentaenoic acid (EPA) levels in study participants' blood. It wasn't even close, with Lypdiso demonstrating a 46% increase in EPA from baseline compared to Vascepa.
Image source: Getty Images.
Source Fool.com
